Last reviewed · How we verify

Tabrecta — Competitive Intelligence Brief

Tabrecta (CAPMATINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor. Area: Oncology.

marketed Kinase Inhibitor Hepatocyte growth factor receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tabrecta (CAPMATINIB) — Novartis Pharm. Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tabrecta TARGET CAPMATINIB Novartis Pharm marketed Kinase Inhibitor Hepatocyte growth factor receptor 2020-01-01
Xalkori Crizotinib Pfizer marketed Kinase Inhibitor [EPC] Hepatocyte growth factor receptor 2011-01-01
Xalkori crizotinib Pfizer marketed Kinase Inhibitor [EPC] Hepatocyte growth factor receptor 2011-01-01
RYBREVANT AMIVANTAMAB-VMJW JANSSEN BIOTECH marketed Epidermal growth factor receptor, Hepatocyte growth factor receptor
(CARBAMIDE®) (CARBAMIDE®) German University in Cairo marketed Cyclin-dependent kinase-like 5, Hepatocyte growth factor receptor
Onartuzumab (MetMab) Onartuzumab (MetMab) Genentech, Inc. phase 3 MET inhibitor monoclonal antibody MET (hepatocyte growth factor receptor)
Wayrilz RILZABRUTINIB Genzyme Corp marketed Kinase Inhibitor [EPC] 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor class)

  1. Novartis · 5 drugs in this class
  2. Pfizer · 3 drugs in this class
  3. Bayer · 2 drugs in this class
  4. Boehringer Ingelheim · 2 drugs in this class
  5. Hoffmann-La Roche · 1 drug in this class
  6. Exelixis Inc · 1 drug in this class
  7. Novartis Pharm · 1 drug in this class
  8. Osi Pharms · 1 drug in this class
  9. Exelixis · 1 drug in this class
  10. Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tabrecta — Competitive Intelligence Brief. https://druglandscape.com/ci/capmatinib. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: